Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Analysis of Liquidity Ratios

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Liquidity Ratios (Summary)

Merck & Co. Inc., liquidity ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Current ratio
Quick ratio
Cash ratio

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The liquidity position of the company exhibits fluctuating trends over the five-year period. Generally, liquidity ratios demonstrate an improvement from 2021 to 2025, though with some intermediate declines. These fluctuations suggest potential shifts in working capital management and short-term asset allocation.

Current Ratio
The current ratio increased from 1.27 in 2021 to 1.47 in 2022, indicating improved ability to cover short-term liabilities with short-term assets. A subsequent decrease to 1.25 in 2023 suggests a potential tightening of liquidity. The ratio then recovered to 1.36 in 2024 and further improved to 1.54 in 2025, reaching its highest point in the observed period. This final increase indicates a strengthening short-term financial position.
Quick Ratio
The quick ratio followed a similar pattern to the current ratio, rising from 0.73 in 2021 to 0.93 in 2022. A decline to 0.68 in 2023 was observed, representing a reduction in the ability to meet short-term obligations with the most liquid assets. The quick ratio then increased to 0.84 in 2024 and reached 0.93 in 2025, mirroring the improvement seen in the current ratio and suggesting enhanced immediate liquidity.
Cash Ratio
The cash ratio demonstrated more volatility. It increased from 0.34 in 2021 to 0.54 in 2022, indicating a greater proportion of current assets held as cash. A decrease to 0.28 in 2023 suggests a deployment of cash into other assets. The ratio then rose to 0.48 in 2024 and further to 0.51 in 2025, indicating a rebuilding of cash reserves, though remaining below the 2022 peak. This suggests a dynamic approach to cash management.

Overall, the company’s liquidity appears to be strengthening towards the end of the period, as evidenced by the increasing trends in all three ratios. However, the intermediate declines in 2023 warrant further investigation to understand the underlying causes and potential impacts on operational flexibility.


Current Ratio

Merck & Co. Inc., current ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Current Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Current Ratio, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The current ratio exhibited fluctuations over the five-year period. Initially, the ratio increased before stabilizing and then increasing again in the final year observed. This suggests a dynamic relationship between the company’s short-term assets and liabilities.

Current Ratio Trend
The current ratio began at 1.27 in 2021, indicating the company possessed $1.27 of current assets for every $1.00 of current liabilities. An improvement was noted in 2022, with the ratio rising to 1.47, representing enhanced short-term solvency. A slight decrease occurred in 2023, with the ratio falling to 1.25. The ratio then increased to 1.36 in 2024, before reaching 1.54 in 2025, the highest value within the observed period.

The increase in the current ratio from 2021 to 2022 suggests improved liquidity, potentially due to an increase in current assets or a decrease in current liabilities. The subsequent dip in 2023 could be attributed to a faster growth rate in current liabilities compared to current assets. The final increase in 2025 indicates a strengthening of the company’s ability to meet its short-term obligations.

Underlying Components
Current assets increased from $30,266 million in 2021 to $43,516 million in 2025, with intermediate fluctuations. Current liabilities also increased, moving from $23,872 million in 2021 to $28,327 million in 2025, but at a slower pace than the growth in current assets, particularly in the final two years. This differential growth rate contributed to the observed trend in the current ratio.

Overall, the current ratio demonstrates a generally positive trend, with the company exhibiting an increasing capacity to cover its short-term liabilities with its short-term assets. The fluctuations suggest a responsive management of working capital, adapting to changing business conditions.


Quick Ratio

Merck & Co. Inc., quick ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Short-term investments
Accounts receivable, net of allowance for doubtful accounts
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Quick Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Quick Ratio, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The quick ratio exhibited fluctuations over the five-year period. Initially, the ratio increased before declining and then recovering to a level comparable to its peak. This suggests a dynamic relationship between the company’s most liquid assets and its short-term obligations.

Quick Ratio Trend
The quick ratio began at 0.73 in 2021, increasing to 0.93 in 2022. A subsequent decrease was observed in 2023, with the ratio falling to 0.68. The ratio then improved to 0.84 in 2024 and further increased to 0.93 in 2025, matching the high observed in 2022.
Quick Asset Movement
Total quick assets increased from US$17,326 million in 2021 to US$22,642 million in 2022. A decrease to US$17,442 million was noted in 2023, followed by increases to US$23,967 million in 2024 and US$26,340 million in 2025. This movement in quick assets appears to correlate with the fluctuations in the quick ratio.
Current Liability Movement
Current liabilities demonstrated a generally increasing trend throughout the period. From US$23,872 million in 2021, they rose to US$24,239 million in 2022, then to US$25,694 million in 2023, and further to US$28,420 million in 2024. A slight decrease to US$28,327 million was observed in 2025. The consistent rise in current liabilities likely contributed to the initial decline in the quick ratio in 2023.

The recovery of the quick ratio in 2024 and 2025 suggests that the growth in quick assets outpaced the increase in current liabilities during those years. The final value of 0.93 in 2025 indicates a strengthening short-term liquidity position compared to the beginning of the period.


Cash Ratio

Merck & Co. Inc., cash ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Short-term investments
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Cash Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Cash Ratio, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The cash ratio exhibited fluctuations over the five-year period. Initially, the ratio increased significantly before declining and then stabilizing. Total cash assets and current liabilities both influenced these changes.

Cash Ratio Trend
The cash ratio began at 0.34 in 2021, representing the proportion of current liabilities covered by total cash assets. A substantial increase was observed in 2022, reaching 0.54. This indicates a strengthened immediate liquidity position. However, the ratio decreased to 0.28 in 2023, suggesting a weakening in the company’s ability to cover short-term obligations with only cash. A partial recovery occurred in 2024, with the ratio rising to 0.48, and this level was largely maintained in 2025 at 0.51.
Total Cash Assets
Total cash assets increased considerably from US$8,096 million in 2021 to US$13,192 million in 2022. A subsequent decrease to US$7,093 million was noted in 2023. Cash assets then increased again, reaching US$13,689 million in 2024 and further growing to US$14,565 million in 2025. These fluctuations directly impacted the cash ratio.
Current Liabilities
Current liabilities demonstrated a generally increasing trend throughout the period. Starting at US$23,872 million in 2021, they rose to US$24,239 million in 2022, then to US$25,694 million in 2023. Further increases were observed in 2024 (US$28,420 million) and 2025 (US$28,327 million). The relatively stable level of current liabilities in the final year may have contributed to the stabilization of the cash ratio.

The interplay between cash asset levels and current liabilities resulted in the observed cash ratio pattern. While the company experienced periods of strong cash positions, the consistent growth in current liabilities moderated the overall liquidity indicated by this ratio.